Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

NCT05261386
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-008
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Chalazion, Dry Eye Syndromes
Interventions
LipiFlow System
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Boston, Massachusetts • Winchester, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

NCT06542276
Conditions
MGD-Meibomian Gland Dysfunction
Interventions
Thermal Vectored Pulsation
Device
Lead sponsor
Dunes Eye Consultants
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dakota Dunes, South Dakota
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Conditions
Dry Eye Disease
Interventions
Propylene glycol-based eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Kansas City, Missouri • Norfolk, Virginia
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye

NCT00832130
Conditions
Chalazion, Dry Eye Syndromes
Interventions
Manual Mini System, iHeat Portable Warm Compress Therapy
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
Fayetteville, Arkansas • Morrow, Georgia • Highland Park, Illinois + 8 more
Completed Not applicable Interventional Accepts healthy volunteers

Lipiflow vs iLux Patient Acceptance and Comfort Study

NCT04454983
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Lipiflow Thermal Pulsation System, iLux System
Device
Lead sponsor
Epstein, Arthur B., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease
Interventions
Zocular Eyelid System Treatment
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
Conditions
Dry Eye, Meibomian Gland Dysfunction (Disorder)
Interventions
Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).
Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Meibomian Gland Dysfunction
Interventions
AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01%, AGN-195263 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 29 more
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more
Not yet recruiting Not applicable Interventional

TearCare in Young Adults

NCT07579156
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
TearCare®
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Conditions
Meibomian Gland Dysfunction
Interventions
meibomian gland probing, Left eye Meibomian Gland Probing Control Group
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions
Vehicle of TP-03
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Northridge, California • Shelby, North Carolina
Conditions
Evaporative Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
ELM
Device
Lead sponsor
Eyedetec Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Citrus Heights, California
Conditions
Dry Eye Syndrome
Interventions
IPL, Sham IPL, MGX
Device · Procedure
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee • Austin, Texas
Conditions
Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
IPL_RF_MGX
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York • Harrisburg, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Contact Lens Comfort Relative to Meibomian Gland Status

NCT01819194
Conditions
Meibomian Gland Dysfunction
Interventions
senofilcon A
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fullerton, California